Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;330:905 (16 April), doi:10.1136/bmj.330.7496.905
| The first 150 words of the full text of this article appear below. |
EDITORCohen et al suggest that prescription drugs become candidates for switching to being available over the counter if they meet three criteria: use for non-chronic conditions, easy to self diagnose, low potential for misuse.1 Whether this is the policy of drug regulators is unclear.
Perhaps this view is drawn from examination of current over the counter products? Drugs available over the counter generally meet these criteria; therefore they must be the basis for approving switches. Could this be a chicken and egg scenario?
Most switches are instigated by the manufacturers to generate profits. This requires a potential market for the switched drug, which itself relies on consumers recognising the need for the drug and being motivated to buy it. People less involved in their own health might not see the need for preventive drugs, making switching likely to fail owing to poor sales. So the manufacturers never apply
Magnus Hird, pharmacist practitioner
Bloomfield Medical Centre, Blackpool FY1 6JW Magnus.hird@blueyonder.co.uk